iTeos Therapeutics is a privately held, next-generation immune-oncology company dedicated to extending and improving the lives of people with cancer by designing and developing innovative immunotherapies.
The Company is advancing EOS850, a best-in-class, highly-selective and non-brain penetrant adenosine A2A receptor antagonist, into multiple Phase 1b/2a clinical trials in 2Q2020.
iTeos’s second clinical program, a fully human, ADCC-enabling anti-TIGIT antibody (EOS448) entered the clinic in February 2020.
Headquartered in Cambridge, MA with a world-class research center in Gosselies, Belgium, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011.
In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital, Curative Ventures, and SFPI. Previous investors also participated.